315
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Imbalance of Vaginal Microbiota and Immunity: Two Main Accomplices of Cervical Cancer in Chinese Women

, , , , , , & show all
Pages 987-1002 | Received 14 Feb 2023, Accepted 27 Jun 2023, Published online: 04 Jul 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
  • National Health Commission of The People’s Republic of China. Chinese guidelines for diagnosis and treatment of cervical cancer 2018 (English version). Chin J Cancer Res. 2019;31(2):295–305. doi:10.21147/j.issn.1000-9604.2019.02.04
  • Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–899. doi:10.1016/S0140-6736(13)60022-7
  • Balasubramaniam SD, Balakrishnan V, Oon CE, Kaur G. Key molecular events in cervical cancer development. Medicina. 2019;55(7):384. doi:10.3390/medicina55070384
  • Hu Z, Ding M. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018;7(10):5217–5236. doi:10.1002/cam4.1501
  • Fan Q, Ting H, Xiao S, et al. HPV-16/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1. Mol Carcinog. 2021;60(5):313–330. doi:10.1002/mc.23292
  • Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci. 2017;131(17):2201–2221. doi:10.1042/CS20160786
  • Chase D, Goulder A, Zenhausern F, Monk B, Herbst-Kralovetz M. The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment. Gynecol Oncol. 2015;138(1):190–200. doi:10.1016/j.ygyno.2015.04.036
  • Mitra A, MacIntyre DA, Marchesi JR, et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome. 2016;4(1):58. doi:10.1186/s40168-016-0203-0
  • Norenhag J, Du J, Olovsson M, et al. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG. 2020;127(2):171–180. doi:10.1111/1471-0528.15854
  • Li Y, Yu T, Yan H, et al. Vaginal microbiota and HPV infection: novel mechanistic insights and therapeutic strategies. Infect Drug Resist. 2020;13:1213–1220. doi:10.2147/IDR.S210615
  • Champer M, Wong AM, Champer J, et al. The role of the vaginal microbiome in gynaecological cancer. BJOG. 2018;125(3):309–315. doi:10.1111/1471-0528.14631
  • Rose WA, McGowin CL, Spagnuolo RA, et al. Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures. PLoS One. 2012;7(3):e32728. doi:10.1371/journal.pone.0032728
  • Nicolò S, Tanturli M, Mattiuz G, et al. Vaginal lactobacilli and vaginal dysbiosis-associated bacteria differently affect cervical epithelial and immune homeostasis and anti-viral defenses. Int J Mol Sci. 2021;22(12):6487. doi:10.3390/ijms22126487
  • Sommer F, Bäckhed F. The gut microbiota--masters of host development and physiology. Nature Rev. 2013;11(4):227–238. doi:10.1038/nrmicro2974
  • Brinkman JA, Hughes SH, Stone P, et al. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers. 2007;23(4):337–352. doi:10.1155/2007/245146
  • Borgdorff H, Gautam R, Armstrong SD, et al. Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier. Mucosal Immunol. 2016;9(3):621–633. doi:10.1038/mi.2015.86
  • Libby EK, Pascal KE, Mordechai E, Adelson ME, Trama JP. Atopobium vaginae triggers an innate immune response in an in vitro model of bacterial vaginosis. Microbes Infect. 2008;10(4):439–446. doi:10.1016/j.micinf.2008.01.004
  • Vitkauskaite A, Urboniene D, Celiesiute J, et al. Circulating inflammatory markers in cervical cancer patients and healthy controls. J Immunotoxicol. 2020;17(1):105–109. doi:10.1080/1547691X.2020.1755397
  • Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, et al. Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. PLoS One. 2016;11(4):e0153274. doi:10.1371/journal.pone.0153274
  • You X, Wang Y, Meng J, et al. Exosomal miR‑663b exposed to TGF‑β1 promotes cervical cancer metastasis and epithelial‑mesenchymal transition by targeting MGAT3. Oncol Rep. 2021;45(4):12. doi:10.3892/or.2021.7963
  • Valle-Mendiola A, Gutiérrez-Hoya A, Lagunas-Cruz C, et al. Pleiotropic effects of IL-2 on cancer: its role in cervical cancer. Mediators Inflamm. 2016;2016:2849523. doi:10.1155/2016/2849523
  • Bonin-Jacob CM, Almeida-Lugo LZ, Puga MAM, et al. IL-6 and IL-10 in the serum and exfoliated cervical cells of patients infected with high-risk human papillomavirus. PLoS One. 2021;16(3):e0248639. doi:10.1371/journal.pone.0248639
  • Brooks DG, Trifilo MJ, Edelmann KH, et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12(11):1301–1309. doi:10.1038/nm1492
  • Chen X, Han S, Wang S, et al. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res. 2009;15(1):400–405. doi:10.1158/1078-0432.CCR-08-1829
  • Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer? Transl Res. 2017;179:168–182. doi:10.1016/j.trsl.2016.07.004
  • Salas-Jara MJ, Ilabaca A, Vega M, García A. Biofilm forming lactobacillus: new challenges for the development of probiotics. Microorganisms. 2016;4(3):35. doi:10.3390/microorganisms4030035
  • Manca S, Upadhyaya B, Mutai E, et al. Milk exosomes are bioavailable and distinct microRNA cargos have unique tissue distribution patterns. Sci Rep. 2018;8(1):11321. doi:10.1038/s41598-018-29780-1
  • Anahtar MN, Byrne E, Doherty K, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 2015;42(5):965–976. doi:10.1016/j.immuni.2015.04.019
  • Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife. 2013;2:e01202. doi:10.7554/eLife.01202
  • Berezow AB, Darveau RP. Microbial shift and periodontitis. Periodontology. 2011;55(1):36–47. doi:10.1111/j.1600-0757.2010.00350.x
  • Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017;151(4):363–374. doi:10.1111/imm.12760
  • Di Paola M, Sani C, Clemente AM, et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk human papillomavirus infection. Sci Rep. 2017;7(1):10200. doi:10.1038/s41598-017-09842-6
  • Wang KD, Xu DJ, Wang BY, Yan DH, Lv Z, Su JR. Inhibitory effect of vaginal lactobacillus supernatants on cervical cancer cells. Probiotics Antimicrob Proteins. 2018;10(2):236–242. doi:10.1007/s12602-017-9339-x
  • Chen Y, Qiu X, Wang W, et al. Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort. BMC Infect Dis. 2020;20(1):629. doi:10.1186/s12879-020-05324-9
  • Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat Med. 2019;25(10):1500–1504. doi:10.1038/s41591-019-0600-6
  • Ling Z, Kong J, Liu F, et al. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genom. 2010;11:488. doi:10.1186/1471-2164-11-488
  • Rosca AS, Castro J, Sousa LGV, Cerca N. Gardnerella and vaginal health: the truth is out there. FEMS Microbiol Rev. 2020;44(1):73–105. doi:10.1093/femsre/fuz027
  • Ravel J, Moreno I, Simón C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am J Obstet Gynecol. 2021;224(3):251–257. doi:10.1016/j.ajog.2020.10.019
  • Ruffilli I, Ferrari SM, Colaci M, et al. IP-10 in autoimmune thyroiditis. Hormone Metabol Res. 2014;46(9):597–602. doi:10.1055/s-0034-1382053
  • Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16(1):1–4. doi:10.1016/S1074-7613(01)00261-8
  • Kaur US, Shet A, Rajnala N, et al. High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy. Sci Rep. 2018;8(1):17679. doi:10.1038/s41598-018-35877-4
  • Hoermannsperger G, Clavel T, Hoffmann M, et al. Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation. PLoS One. 2009;4(2):e4365. doi:10.1371/journal.pone.0004365
  • von Schillde M-A, Hörmannsperger G, Weiher M. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host Microbe. 2012;11(4):387–396. doi:10.1016/j.chom.2012.02.006
  • Masson L, Barnabas S, Deese J, et al. Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study. Sex Transm Infect. 2019;95(1):5–12. doi:10.1136/sextrans-2017-053506
  • Torcia MG. Interplay among vaginal microbiome, immune response and sexually transmitted viral infections. Int J Mol Sci. 2019;20(2):266. doi:10.3390/ijms20020266
  • de Castro-Sobrinho JM, Rabelo-Santos SH, Fugueiredo-Alves RR. Bacterial vaginosis and inflammatory response showed association with severity of cervical neoplasia in HPV-positive women. Diagn Cytopathol. 2016;44(2):80–86. doi:10.1002/dc.23388
  • Mastromarino P, Di Pietro M, Schiavoni G, et al. Effects of vaginal lactobacilli in Chlamydia trachomatis infection. Int J Med Microbiol. 2014;304(5–6):654–661. doi:10.1016/j.ijmm.2014.04.006
  • Kochumon S, Al-Sayyar A, Jacob T, et al. TNF-α increases IP-10 expression in MCF-7 breast cancer cells via activation of the JNK/c-Jun pathways. Biomolecules. 2021;11(9):1355. doi:10.3390/biom11091355
  • Clark AM, Heusey HL, Griffith LG, et al. IP-10 (CXCL10) can trigger emergence of dormant breast cancer cells in a metastatic liver microenvironment. Front Oncol. 2021;11:676135. doi:10.3389/fonc.2021.676135
  • Lunardi S, Lim SY, Muschel RJ, et al. IP-10/CXCL10 attracts regulatory T cells: implication for pancreatic cancer. Oncoimmunology. 2015;4(9):e1027473. doi:10.1080/2162402X.2015.1027473
  • Shibahara T, Wilcox JN, Couse T, Madara JL. Characterization of epithelial chemoattractants for human intestinal intraepithelial lymphocytes. Gastroenterology. 2001;120(1):60–70. doi:10.1053/gast.2001.20904
  • Kim HJ, Song DE, Lim SY, et al. Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumor-infiltrating lymphocytes. PLoS One. 2011;6(10):e26264. doi:10.1371/journal.pone.0026264
  • Herder C, Baumert J, Thorand B, et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002. Diabetologia. 2006;49(5):921–929. doi:10.1007/s00125-006-0190-y
  • Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol. 2006;176(7):4235–4243. doi:10.4049/jimmunol.176.7.4235
  • Bertolino P, Bowen DG, McCaughan GW, Fazekas de St Groth B. Antigen-specific primary activation of CD8+ T cells within the liver. J Immunol. 2001;166(9):5430–5438. doi:10.4049/jimmunol.166.9.5430
  • Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol. 2012;24(2):188–193. doi:10.1016/j.ceb.2012.02.002
  • Yang L, Lin Z, Huang Q, et al. Effect of vascular endothelial growth factor on remodeling of C6 glioma tissue in vivo. J Neurooncol. 2011;103(1):33–41. doi:10.1007/s11060-010-0356-9
  • da Silva L, Neves BM, Moura L, Cruz MT, Carvalho E. Neurotensin downregulates the pro-inflammatory properties of skin dendritic cells and increases epidermal growth factor expression. Biochim Biophys Acta. 2011;1813(10):1863–1871. doi:10.1016/j.bbamcr.2011.06.018
  • Braicu EI, Gasimli K, Richter R, et al. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO Phase III clinical trial. Anticancer Res. 2014;34(1):385–391.
  • Akaza H, Oya M, Iijima M, et al. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance. Jpn J Clin Oncol. 2015;45(10):953–962. doi:10.1093/jjco/hyv099
  • Mitra A, MacIntyre DA, Paraskevaidi M, et al. The vaginal microbiota and innate immunity after local excisional treatment for cervical intraepithelial neoplasia. Genome Med. 2021;13(1):176. doi:10.1186/s13073-021-00977-w
  • Mei C, Yang W, Wei X, Wu K, Huang D. The unique microbiome and innate immunity during pregnancy. Front Immunol. 2019;10:2886. doi:10.3389/fimmu.2019.02886
  • Zheng JJ, Miao JR, Wu Q, et al. Correlation between HPV-negative cervical lesions and cervical microenvironment. Taiwan J Obstet Gynecol. 2020;59(6):855–861. doi:10.1016/j.tjog.2020.08.002
  • Mortaki D, Gkegkes ID, Psomiadou V, et al. Vaginal microbiota and human papillomavirus: a systematic review. J Turk German Gynecol Assoc. 2020;21(3):193–200. doi:10.4274/jtgga.galenos.2019.2019.0051
  • Chee WJY, Chew SY, Than LTL. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microb Cell Fact. 2020;19(1):203. doi:10.1186/s12934-020-01464-4
  • Shannon B, Yi TJ, Perusini S, et al. Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. Mucosal Immunol. 2017;10(5):1310–1319. doi:10.1038/mi.2016.129